Chitosan-Imidazolium Core-Shell Nanoparticles of Gd-Mn-Mo Polyoxometalate as Novel Potential MRI Nano-Agent for Breast Cancer Detection.
breast cancer
chitosan–imidazolium (CSIm)
gadolinium–manganese–molybdenum polyoxometalate (POM)
magnetic resonance imaging
nanoparticles
Journal
Micromachines
ISSN: 2072-666X
Titre abrégé: Micromachines (Basel)
Pays: Switzerland
ID NLM: 101640903
Informations de publication
Date de publication:
27 Mar 2023
27 Mar 2023
Historique:
received:
28
02
2023
revised:
14
03
2023
accepted:
24
03
2023
medline:
8
7
2023
pubmed:
8
7
2023
entrez:
8
7
2023
Statut:
epublish
Résumé
Polyoxometalates (POMs) are mineral nanoclusters with many advantages in various diagnostic fields, in particular cancer detection. This study aimed to synthesize and evaluate the performance of gadolinium-manganese-molybdenum polyoxometalate (Gd-Mn-Mo; POM) nanoparticles coated with chitosan-imidazolium (POM@CSIm NPs) for detecting 4T1 breast cancer cells by magnetic resonance imaging in vitro and in vivo. The POM@Cs-Im NPs were fabricated and characterized by FTIR, ICP-OES, CHNS, UV-visible, XRD, VSM, DLS, Zeta potential, and SEM. Cytotoxicity, cellular uptake, and MR imaging in vivo and in vitro of L929 and 4T1 cells were also assessed. The efficacy of nanoclusters was demonstrated using MR images of BALB/C mice bearing a 4T1 tumor in vivo. The evaluation of the in vitro cytotoxicity of the designed NPs showed their high biocompatibility. In fluorescence imaging and flow cytometry, NPs had a higher uptake rate by 4T1 than L929 (
Identifiants
pubmed: 37420974
pii: mi14040741
doi: 10.3390/mi14040741
pmc: PMC10143193
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Isfahan University of Medical Sciences
ID : 3400413
Références
J Biomater Appl. 2021 Feb;35(7):857-868
pubmed: 32854570
Int J Biol Macromol. 2018 Sep;116:849-862
pubmed: 29730001
Sci Rep. 2015 Feb 24;5:8549
pubmed: 25707374
Angew Chem Int Ed Engl. 2019 Mar 4;58(10):2980-2999
pubmed: 29893459
IET Nanobiotechnol. 2021 May;15(3):247-256
pubmed: 34694670
Mater Sci Eng C Mater Biol Appl. 2019 Mar;96:356-364
pubmed: 30606543
J Res Med Sci. 2009 May;14(3):141-7
pubmed: 21772875
Sci Rep. 2019 May 9;9(1):7173
pubmed: 31073222
J Am Chem Soc. 2012 Sep 12;134(36):14982-90
pubmed: 22894703
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Pharm Dev Technol. 2021 Oct;26(8):899-909
pubmed: 34266344
Depress Res Treat. 2020 May 12;2020:5871402
pubmed: 32455010
MAGMA. 2019 Aug;32(4):487-500
pubmed: 30730021
Dalton Trans. 2021 Jun 15;50(23):8076-8083
pubmed: 34018508
Diagnostics (Basel). 2023 Feb 22;13(5):
pubmed: 36899980
Front Bioeng Biotechnol. 2018 Jul 16;6:99
pubmed: 30062094
Biomed Pharmacother. 2018 Oct;106:1513-1526
pubmed: 30119227
Int J Nanomedicine. 2016 Jun 15;11:2785-97
pubmed: 27366061
J Inorg Biochem. 2007 Jul;101(7):1036-42
pubmed: 17524483
Inorg Chem. 2017 Aug 7;56(15):8759-8767
pubmed: 28722450
J Biomater Appl. 2018 Sep;33(3):392-401
pubmed: 30223733
Chemistry. 2021 Apr 12;27(21):6422-6434
pubmed: 33314442
N Engl J Med. 2005 Oct 27;353(17):1784-92
pubmed: 16251534